Quest Diagnostics Inc (DGX) Expected to Post Earnings of $1.54 Per Share

Wall Street brokerages expect that Quest Diagnostics Inc (NYSE:DGX) will report earnings per share of $1.54 for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have provided estimates for Quest Diagnostics’ earnings. The highest EPS estimate is $1.69 and the lowest is $1.41. Quest Diagnostics reported earnings of $1.33 per share in the same quarter last year, which would indicate a positive year over year growth rate of 15.8%. The firm is scheduled to announce its next earnings report on Thursday, April 19th.

According to Zacks, analysts expect that Quest Diagnostics will report full-year earnings of $6.51 per share for the current fiscal year, with EPS estimates ranging from $5.64 to $6.65. For the next year, analysts anticipate that the firm will post earnings of $6.83 per share, with EPS estimates ranging from $6.46 to $7.12. Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that cover Quest Diagnostics.

How to Become a New Pot Stock Millionaire

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings data on Thursday, February 1st. The medical research company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. Quest Diagnostics had a return on equity of 15.41% and a net margin of 10.00%. The company had revenue of $1.94 billion for the quarter, compared to the consensus estimate of $1.93 billion. During the same period in the previous year, the business earned $1.31 EPS. Quest Diagnostics’s revenue for the quarter was up 4.0% compared to the same quarter last year.

Several research firms have issued reports on DGX. Goldman Sachs Group began coverage on Quest Diagnostics in a report on Monday, January 29th. They set a “buy” rating and a $117.00 price objective on the stock. Zacks Investment Research downgraded Quest Diagnostics from a “buy” rating to a “hold” rating in a report on Wednesday. Mizuho set a $113.00 price objective on Quest Diagnostics and gave the stock a “buy” rating in a report on Wednesday, January 24th. Argus upgraded Quest Diagnostics from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $104.14 to $116.00 in a report on Wednesday. Finally, Piper Jaffray Companies reiterated a “hold” rating and issued a $110.00 price target on shares of Quest Diagnostics in a report on Thursday, February 1st. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and nine have assigned a buy rating to the company’s stock. Quest Diagnostics presently has a consensus rating of “Hold” and an average price target of $108.10.

In related news, Chairman Stephen H. Rusckowski sold 106,840 shares of the company’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $107.00, for a total transaction of $11,431,880.00. Following the completion of the transaction, the chairman now directly owns 272,956 shares in the company, valued at approximately $29,206,292. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP J. E. Davis sold 1,798 shares of the company’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $104.42, for a total value of $187,747.16. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 208,358 shares of company stock valued at $21,617,807. 1.75% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Wagner Wealth Management LLC acquired a new position in Quest Diagnostics during the 4th quarter worth $106,000. Fuller & Thaler Asset Management Inc. acquired a new position in Quest Diagnostics during the 4th quarter worth $118,000. Cerebellum GP LLC acquired a new position in Quest Diagnostics during the 4th quarter worth $128,000. Assetmark Inc. boosted its position in Quest Diagnostics by 139.5% during the 4th quarter. Assetmark Inc. now owns 1,473 shares of the medical research company’s stock worth $145,000 after acquiring an additional 858 shares during the period. Finally, Icon Wealth Partners LLC acquired a new position in Quest Diagnostics during the 4th quarter worth $147,000. Hedge funds and other institutional investors own 87.40% of the company’s stock.

Shares of Quest Diagnostics (NYSE DGX) opened at $106.99 on Friday. The company has a current ratio of 1.24, a quick ratio of 1.15 and a debt-to-equity ratio of 0.76. Quest Diagnostics has a twelve month low of $90.10 and a twelve month high of $112.96. The stock has a market capitalization of $14,510.00, a P/E ratio of 22.62, a price-to-earnings-growth ratio of 1.88 and a beta of 0.68.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 18th. Investors of record on Wednesday, April 4th will be paid a dividend of $0.50 per share. This is an increase from Quest Diagnostics’s previous quarterly dividend of $0.45. This represents a $2.00 dividend on an annualized basis and a yield of 1.87%. The ex-dividend date is Tuesday, April 3rd. Quest Diagnostics’s dividend payout ratio is presently 38.05%.

COPYRIGHT VIOLATION WARNING: “Quest Diagnostics Inc (DGX) Expected to Post Earnings of $1.54 Per Share” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://sportsperspectives.com/2018/03/10/quest-diagnostics-inc-dgx-expected-to-post-earnings-of-1-54-per-share.html.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Get a free copy of the Zacks research report on Quest Diagnostics (DGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply